Key result
Exon-skipping and trans-splicing have been identified as the most optimal gene therapy approaches for the etiotropic treatment of dysferlinopathies.
Why the study?
There are various pathogenetic and symptomatic treatments for hereditary muscular dystrophies, but very few registered drugs exist for etiological treatment.
Answers are grounded in this paper and cite their sources.
This review highlights exon-skipping and trans-splicing as the most optimal gene therapy approaches for the etiotropic treatment of dysferlinopathies.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Ivanova et al. (2021) conducted a review in Dysferlinopathy. Gene therapy (exon skipping, trans-splicing) was evaluated. Exon-skipping and trans-splicing have been identified as the most optimal gene therapy approaches for the etiotropic treatment of dysferlinopathies.
Synapse has enriched 10 related papers. Consider them for comparative context: